Fig. 3
From: Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer
Kaplan-Meier analysis with a log-rank test of survival. a and c The disease-free survival (DFS) and b and d 5-year overall survival (OS) of patients were associated with KPNA2 expression that was determined by immunohistochemical staining. DFS and OS were significantly shorter in patients with KPNA2 high expression tumors than in those with KPNA2 low expression tumors